Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BIIB

BIIB - Biogen Inc Stock Price, Fair Value and News

$174.82+0.70 (+0.40%)
Market Closed

62/100

BIIB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

62/100

BIIB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$188.75

Target 3M

$175.71

Target 6M

$180

BIIB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIIB Price Action

Last 7 days

1.3%

Last 30 days

-1.1%

Last 90 days

16.9%

Trailing 12 Months

20.2%

BIIB RSI Chart

BIIB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIIB Valuation

Market Cap

25.6B

Price/Earnings (Trailing)

15.94

Price/Sales (Trailing)

2.55

EV/EBITDA

9.59

Price/Free Cashflow

11.13

BIIB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$188.75

Target 3M

$175.71

Target 6M

$180

BIIB Fundamentals

BIIB Revenue

Revenue (TTM)

10.1B

Rev. Growth (Yr)

2.79%

Rev. Growth (Qtr)

-4.19%

BIIB Earnings

Earnings (TTM)

1.6B

Earnings Growth (Yr)

20.08%

Earnings Growth (Qtr)

-26.51%

BIIB Profitability

Operating Margin

94.58%

EBT Margin

18.92%

Return on Equity

8.83%

Return on Assets

5.51%

Free Cashflow Yield

8.99%

BIIB Investor Care

Shares Dilution (1Y)

0.67%

Diluted EPS (TTM)

10.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20259.8B10.0B10.1B0
20249.7B9.7B9.6B9.7B
202310.1B10.0B10.0B9.8B
202210.8B10.6B10.4B10.2B
202112.6B11.7B11.1B11.0B
202014.4B14.5B14.3B13.4B
201913.8B14.1B14.2B14.4B
201812.6B12.9B13.2B13.5B
201711.5B11.7B11.8B12.3B
201610.9B11.2B11.4B11.4B
201510.1B10.3B10.6B10.8B
20147.6B8.3B9.0B9.7B
20135.6B5.9B6.4B6.9B
20125.1B5.3B5.4B5.5B
20114.8B4.8B4.9B5.0B
20100004.7B
Get all data in R, Python etc through our Historical Stock Data APIs

About Biogen Inc

BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEbiogen.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES8725

Biogen Inc Frequently Asked Questions

BIIB is the stock ticker symbol of Biogen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Biogen Inc is 25.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BIIB's fair value in chart for subscribers.

The fair value guage provides a quick view whether BIIB is over valued or under valued. Whether Biogen Inc is cheap or expensive depends on the assumptions which impact Biogen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIIB.

As of Wed Jan 28 2026, BIIB's PE ratio (Price to Earnings) is 15.94 and Price to Sales (PS) ratio is 2.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIIB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Biogen Inc has provided -0.044 (multiply by 100 for percentage) rate of return.